Harmony Biosciences (HRMY) to Release Earnings on Tuesday

Key Points

• Harmony Biosciences is set to release its Q2 2025 earnings on August 5th, with estimates of $0.78 earnings per share and $204.37 million in revenue.
• The company's last quarter saw earnings of $0.78 per share, exceeding estimates, and revenue increased by 19.5% year-over-year.
• Brokerages have rated Harmony Biosciences favorably, with an average rating of "Buy" and a consensus price target of $51.00.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) is expected to be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 5th. Analysts expect the company to announce earnings of $0.78 per share and revenue of $204.37 million for the quarter. Harmony Biosciences has set its FY 2025 guidance at EPS.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. The firm had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. Harmony Biosciences had a net margin of 20.53% and a return on equity of 24.32%. The business's quarterly revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. On average, analysts expect Harmony Biosciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Harmony Biosciences Price Performance

NASDAQ HRMY traded down $0.69 on Friday, hitting $34.49. The company had a trading volume of 367,805 shares, compared to its average volume of 663,468. The company has a market capitalization of $1.98 billion, a PE ratio of 13.16, a PEG ratio of 0.48 and a beta of 0.83. The company's fifty day moving average price is $34.09 and its 200-day moving average price is $33.99. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.67 and a quick ratio of 3.63. Harmony Biosciences has a 12-month low of $26.47 and a 12-month high of $41.61.

Analyst Ratings Changes

Several brokerages recently commented on HRMY. HC Wainwright reissued a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Cantor Fitzgerald raised shares of Harmony Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Truist Financial began coverage on shares of Harmony Biosciences in a report on Monday, July 21st. They issued a "buy" rating and a $48.00 price target for the company. The Goldman Sachs Group began coverage on shares of Harmony Biosciences in a report on Thursday, July 10th. They issued a "neutral" rating and a $33.00 price target for the company. Finally, Oppenheimer started coverage on shares of Harmony Biosciences in a report on Monday, June 2nd. They issued an "outperform" rating and a $61.00 price target for the company. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $51.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Harmony Biosciences by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company's stock valued at $752,000 after acquiring an additional 984 shares during the last quarter. Amundi boosted its position in shares of Harmony Biosciences by 115.6% during the 1st quarter. Amundi now owns 39,668 shares of the company's stock valued at $1,229,000 after acquiring an additional 21,266 shares during the last quarter. Empowered Funds LLC acquired a new position in shares of Harmony Biosciences during the 1st quarter valued at about $2,330,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Harmony Biosciences by 53.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company's stock valued at $3,166,000 after acquiring an additional 33,058 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.